Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or
Menu

Sanofi-Aventis Sa (SNY)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (BATS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ fieldTitles[key] ]] [[ value ]] [[ value ]]
[[ ctrl.chartTitle ]]
Full Chart

Fundamentals

See More
  • Market Capitalization, $K 125,949,424
  • Shares Outstanding, K 2,521,510
  • Annual Sales, $ 38,408 M
  • Annual Income, $ 4,864 M
  • 36-Month Beta 0.88
  • Price/Sales 3.36
  • Price/Cash Flow 10.82
  • Price/Book 1.98

Price Performance

See More
Period Period Low Period High Performance
1-Month
48.07 +4.72%
on 08/30/17
50.65 -0.61%
on 09/22/17
+1.88 (+3.88%)
since 08/22/17
3-Month
46.79 +7.59%
on 07/19/17
50.65 -0.61%
on 09/22/17
+0.73 (+1.47%)
since 06/22/17
52-Week
36.81 +36.76%
on 10/26/16
50.65 -0.61%
on 09/22/17
+11.77 (+30.52%)
since 09/22/16

Most Recent Stories

More News
Alnylam/Sanofi's RNAi Drug Meets Endpoint in Study, Stock Up

Alnylam (ALNY) and partner Sanofi RNAi therapeutic patisiran met its primary efficacy endpoint and all secondary endpoints in the phase III APOLLO study.

ALNY : 113.80 (+0.78%)
REGN : 432.72 (-0.17%)
SNY : 50.34 (+0.78%)
ALXN : 142.82 (-0.07%)
Is Sanofi (SNY) a Great Stock for Value Investors?

Let's see if Sanofi (SNY) stock is a good choice for value-oriented investors right now from multiple angles.

SNY : 50.34 (+0.78%)
Sanofi and NIH researchers develop "three-in-one" antibodies as a potential breakthrough intervention for HIV/AIDS

In a landmark study published in the journal Science today, researchers produced genetically engineered antibodies with the highest activity and breadth of coverage yet seen against human immunodeficiency...

SAN : 6.83 (+0.59%)
SNY : 50.34 (+0.78%)
Alnylam and Sanofi Report Positive Topline Results from APOLLO Phase 3 Study of Patisiran in Hereditary ATTR (hATTR) Amyloidosis Patients with Polyneuropathy

--- Alnylam Intends to File New Drug Application (NDA) in Late 2017 and Marketing Authorisation Application (MAA) in Early 2018 -

SAN : 6.83 (+0.59%)
ALNY : 113.80 (+0.78%)
SNY : 50.34 (+0.78%)
Huge Supply Shortage Looms for Canada's Newest Industry

The U.S. marijuana market is forecast to reach $25 billion by 2020, with recreational use currently legalized in only two states, while the Canadian pot market forecast to be worth about $8 billion, and...

IIPR : 18.06 (+2.73%)
MEDFF : 7.3679 (-1.71%)
HMMJ.TO : 9.32 (-0.43%)
LEAF.TO : 9.14 (-1.19%)
BLEVF : 1.0825 (-4.37%)
CODI : 17.05 (+0.29%)
SNY : 50.34 (+0.78%)
Regeneron and Sanofi Announce Positive Study Results for DUPIXENT® (dupilumab) in Patients With Moderate-to-Severe Atopic Dermatitis

Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) and Sanofi today announced positive results from the Phase 3 CAFÉ study of DUPIXENT® (dupilumab) in adults with moderate-to-severe atopic dermatitis (AD)...

SAN : 6.83 (+0.59%)
REGN : 432.72 (-0.17%)
SNY : 50.34 (+0.78%)
Lilly/Incyte's Baricitinib Meets Endpoint in Eczema Study

Eli Lilly and Company (LLY) and partner Incyte announced that baricitinib met its primary endpoint in a phase II study in people with moderate-to-severe atopic dermatitis.

LLY : 83.91 (+0.70%)
INCY : 110.85 (-3.65%)
REGN : 432.72 (-0.17%)
SNY : 50.34 (+0.78%)
Patient-Driven Dose Titration with Sanofi's Toujeo Improved Blood Glucose Control Without Increasing Hypoglycemia Risk in Real-Life Clinical Practice

A new randomized clinical trial, TAKE CONTROL1, demonstrated better control of blood sugar (HbA1c) without increasing the risk of hypoglycemia in people with type 2 diabetes (T2D) by using Toujeo® (insulin...

SAN : 6.83 (+0.59%)
SNY : 50.34 (+0.78%)
Daily Blood Glucose Measures in Phase 3 Clinical Trials Demonstrated Better Stability with Sanofi's Toujeo® vs. Insulin Glargine 100 Units/mL

In a new analysis1 of late stage clinical trials,2-4 adults with type 2 diabetes treated with Sanofi's Toujeo® (insulin glargine 300 Units/mL, Gla-300) achieved better blood glucose stability than those...

SAN : 6.83 (+0.59%)
SNY : 50.34 (+0.78%)
AstraZeneca's Asthma Candidate Shows Promising Results

AstraZeneca's asthma candidate, benralizumab, showed promising results in patients who experience more frequent exacerbations despite being on standard-of-care medicines.

AZN : 33.95 (+3.47%)
REGN : 432.72 (-0.17%)
SNY : 50.34 (+0.78%)
ALXN : 142.82 (-0.07%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 88% Buy and ranks in the Top 1% of all short term signal directions.

Longer term, the trend strength is Maximum. Long term indicators mostly agree with the trend.

See More

Business Summary

Sanofi-Aventis is a global pharmaceutical company that contributes to enhance life by providing medicines, vaccines, and integrated healthcare solutions adapted to local needs and means primarily in Europe and the United States. The company is engaged in the research, development, manufacture and marketing...

See More

Support & Resistance

2nd Resistance Point 50.88
1st Resistance Point 50.61
Last Price 50.34
1st Support Level 50.11
2nd Support Level 49.88

See More

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.